Cosciens Biopharma Inc Net Income per Employee (CSCI), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Cosciens Biopharma Inc   (CSCI)
 

Cosciens Biopharma Inc Net Income per Employee

CSCI's Quarterly Results, Trends, Rankings, Statistics
Cosciens Biopharma Inc recorded a cumulative net loss of $-10 million during 12 month ending in the fourth quarter 2025.
The Consumer Non Cyclical sector has seen employees of 21 other companies achieving higher income per employee. While Cosciens Biopharma Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 3860.


What is Income per Employee Ratio?






CSCI Net Income per Employee (Dec 31 2025)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2024)
IV. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -369,929 -838,714 -979,286 -933,607 -853,107
CSCI's Total Ranking # 3860 # 0 # # #
Seq. Net Income Change - - - - -


CSCI Net Income per Employee Company Ranking
Within: No.
Personal & Household Products Industry # 22
Consumer Non Cyclical Sector # 161
Overall Market # 3860

Net Income per Employee Statistics
High Average Low
$ 149,536 $ -297,657 $ -811,679
(Dec 31 2018)   (Dec 31 2022)







Companies with similar Income per Employee for 12 month ending Dec 31 2025, within Consumer Non Cyclical Sector Income per Employee Income 12 month ending Dec 31 2025Number of Employees Dec 31 2025


Date modified: 2026-08-30T08:21:21+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.